مقاومت آنتی بیوتیکی به ویژه توسط باکتری های گرم منفی تقریباً یک وضعیت بحرانی ایجاد کرده است. آنتی بیوتیک جدید Zosurabalpin (RG6006) نویدهایی را نشان می دهد. در مطالعات پیش بالینی مشخص شده است که در برابر باکتری های مقاوم به دارو و گرم منفی CRAB موثر است.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of آنتی بیوتیک ها to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of آنتی بیوتیک مقاومت.
بومانی اسینتوباکتر is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available آنتی بیوتیک ها. There is an urgent need for an effective آنتی بیوتیک against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective آنتی بیوتیک. A progress towards this goal has been reported.
Scientists have identified a novel class of آنتی بیوتیک ها namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Zosurabalpin (RG6006) است آنتی بیوتیک candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-بالینی trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame آنتی بیوتیک-resistance mechanism of CARB suggesting زوسورابالپین پتانسیل دارد.
Hence, human بالینی trials have been initiated to check for safety and efficacy زوسورابالپین در درمان عفونت های تهاجمی ناشی از خرچنگ.
***
منابع:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel آنتی بیوتیک class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- هاوزر اس. و همکاران 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against بالینی Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
